Le Lézard
Classified in: Health, Science and technology
Subject: PLW

Gentag's pathbreaking IP now covers all key areas of wireless diagnostics including diagnostic skin patches, immunoassays and lab-on-a-chip technologies.


WASHINGTON, Nov. 13, 2017 /PRNewswire/ -- Gentag, Inc. is pleased to announce the issuance of 30 additional patents in Europe covering wireless lab-on-a-chip (LOC) diagnostic devices.

The company now holds over 100 issued patents covering cell-based consumer and medical diagnostics that are at the apex of personalized medicine, telemedicine and point-of-care testing. These combined technologies allow a range of applications from simple diagnostics (such as a wireless fever detection skin patch) to sophisticated biomarker analyses for precision medicine.

Recent advances in proteomics and artificial intelligence (AI) will scale up the discovery of new biomarkers and monoclonal antibodies that in turn can be used for the creation of low cost advanced diagnostic sensors.

Using the patented Gentag technology, advanced diagnostics can be done on the spot using a single drop of blood or urine on a disposable wireless device.

New protein, biomarker and metabolite patterns can be applied to early disease detection, preventive medicine, immunotherapy and new drug development.

Disposable wireless diagnostic sensors will allow medical professionals and consumers to undertake diagnostics at the point of care in a market expected to hit $96 billion by 2024.

ABOUT THE GENTAG PATENTS

The new patents are issuing under EP 2843848 B1 and complement the already-issued US lab-on-a-chip patent 9,470,699. Gentag's LOC patents cover protein and biomarker quantification, DNA testing and chemical mixing on a small disposable device controlled and read by a cell phone, using NFC or Bluetooth.  The patents are held by Altivera, LLC a Gentag shareholder owned company.

ABOUT GENTAG

Gentag is a visionary company that combines its advanced knowledge in biology, chemistry and microelectronics to convert proteomics into disposable sensors that will revolutionize diagnostics, proactive medicine, nutrition and the everyday lives of consumers worldwide.

 

For licensing or partnership opportunities please contact:


John Peeters

[email protected]

1-240-994-2236

 

SOURCE Gentag, Inc.


These press releases may also interest you

at 19:05
Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
Greenberg Traurig's David Dykeman and Roman Fayerberg to Present at DeviceTalks Boston
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance Provides Notice Following Data Security Incident
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
CHEMISTREE DEBENTUREHOLDERS APPROVE DEBT RESTRUCTURING
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Public Advisory - Fake Viagra seized from Jug City store in Scarborough, ON
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...

at 17:00
GBLT Receives Shareholder Approval for Delisting from TSX Venture Exchange
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV").  Approval for the delisting was received at...

More news about Health...


News published on and distributed by: